🚀 VC round data is live in beta, check it out!
Nautilus Biotechnology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nautilus Biotechnology and similar public comparables like Avacta Group, Genomictree, Pacific Biosciences, CryoPort and more.
Nautilus Biotechnology Overview
About Nautilus Biotechnology
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Founded
2016
HQ
Employees
155
Website
Sectors
Financials (LTM)
EV
$309M
Nautilus Biotechnology Financials
Nautilus Biotechnology reported last 12-month revenue of $209K and negative EBITDA of ($64M).
In the same LTM period, Nautilus Biotechnology generated $149K in gross profit, ($64M) in EBITDA losses, and had net loss of ($64M).
Revenue (LTM)
Nautilus Biotechnology P&L
In the most recent fiscal year, Nautilus Biotechnology reported revenue of — and EBITDA of ($60M).
Nautilus Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $209K | XXX | — | XXX | XXX | XXX |
| Gross Profit | $149K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($64M) | XXX | ($60M) | XXX | XXX | XXX |
| EBITDA Margin | (30694%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (33655%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($64M) | XXX | ($59M) | XXX | XXX | XXX |
| Net Margin | (30382%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nautilus Biotechnology Stock Performance
Nautilus Biotechnology has current market cap of $382M, and enterprise value of $309M.
Market Cap Evolution
Nautilus Biotechnology's stock price is $3.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $309M | $382M | 0.0% | XXX | XXX | XXX | $-0.47 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNautilus Biotechnology Valuation Multiples
Nautilus Biotechnology trades at 1477.4x EV/Revenue multiple, and (4.8x) EV/EBITDA.
EV / Revenue (LTM)
Nautilus Biotechnology Financial Valuation Multiples
As of April 20, 2026, Nautilus Biotechnology has market cap of $382M and EV of $309M.
Equity research analysts estimate Nautilus Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nautilus Biotechnology has a P/E ratio of (6.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $382M | XXX | $382M | XXX | XXX | XXX |
| EV (current) | $309M | XXX | $309M | XXX | XXX | XXX |
| EV/Revenue | 1477.4x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (4.8x) | XXX | (5.1x) | XXX | XXX | XXX |
| EV/EBIT | (4.4x) | XXX | (4.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 2068.4x | XXX | — | XXX | XXX | XXX |
| P/E | (6.0x) | XXX | (6.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nautilus Biotechnology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nautilus Biotechnology Margins & Growth Rates
Nautilus Biotechnology's revenue in the last 12 month grew by 1228%.
Nautilus Biotechnology's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Nautilus Biotechnology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1228% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (30694%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 20118% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nautilus Biotechnology Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nautilus Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacific Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| CryoPort | XXX | XXX | XXX | XXX | XXX | XXX |
| OmniAb | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nautilus Biotechnology M&A Activity
Nautilus Biotechnology acquired XXX companies to date.
Last acquisition by Nautilus Biotechnology was on XXXXXXXX, XXXXX. Nautilus Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nautilus Biotechnology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNautilus Biotechnology Investment Activity
Nautilus Biotechnology invested in XXX companies to date.
Nautilus Biotechnology made its latest investment on XXXXXXXX, XXXXX. Nautilus Biotechnology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nautilus Biotechnology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nautilus Biotechnology
| When was Nautilus Biotechnology founded? | Nautilus Biotechnology was founded in 2016. |
| Where is Nautilus Biotechnology headquartered? | Nautilus Biotechnology is headquartered in United States. |
| How many employees does Nautilus Biotechnology have? | As of today, Nautilus Biotechnology has over 155 employees. |
| Who is the CEO of Nautilus Biotechnology? | Nautilus Biotechnology's CEO is Sujal M. Patel. |
| Is Nautilus Biotechnology publicly listed? | Yes, Nautilus Biotechnology is a public company listed on Nasdaq. |
| What is the stock symbol of Nautilus Biotechnology? | Nautilus Biotechnology trades under NAUT ticker. |
| When did Nautilus Biotechnology go public? | Nautilus Biotechnology went public in 2021. |
| Who are competitors of Nautilus Biotechnology? | Nautilus Biotechnology main competitors are Avacta Group, Genomictree, Pacific Biosciences, CryoPort. |
| What is the current market cap of Nautilus Biotechnology? | Nautilus Biotechnology's current market cap is $382M. |
| What is the current revenue of Nautilus Biotechnology? | Nautilus Biotechnology's last 12 months revenue is $209K. |
| What is the current revenue growth of Nautilus Biotechnology? | Nautilus Biotechnology revenue growth (NTM/LTM) is 1228%. |
| What is the current EV/Revenue multiple of Nautilus Biotechnology? | Current revenue multiple of Nautilus Biotechnology is 1477.4x. |
| Is Nautilus Biotechnology profitable? | No, Nautilus Biotechnology is not profitable. |
| What is the current EBITDA of Nautilus Biotechnology? | Nautilus Biotechnology has negative EBITDA and is not profitable. |
| What is Nautilus Biotechnology's EBITDA margin? | Nautilus Biotechnology's last 12 months EBITDA margin is (30694%). |
| What is the current EV/EBITDA multiple of Nautilus Biotechnology? | Current EBITDA multiple of Nautilus Biotechnology is (4.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.